Candel Therapeutics CADL
NASDAQ CADL
$10.18 +0.02 (+0.20%)
At close: Oct 2, 2026 · 4:00 PM EDT

Candel Therapeutics (CADL) Gains from Sales and Divestitures (2023 - 2025)

Updated

Candel Therapeutics' Gains from Sales and Divestitures was $33,000 in Q4 2025.

Analysis

Candel Therapeutics (CADL) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends

For FY2025, Gains from Sales and Divestitures at Candel Therapeutics came in at -$306,000.

  • In earlier years, Gains from Sales and Divestitures was -$79,000 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Candel Therapeutics 774.88 Mn 774.88 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 33,000.00
Sep 30, 2025 -300,000.00
Dec 31, 2023 -2,000.00
Sep 30, 2023 -3,000.00
Mar 31, 2023 -74,000.00
API Access

Candel Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CADL&period=max&api_key=YOUR_API_KEY